Drug Guide

Generic Name

Losartan Potassium

Brand Names Cozaar, Arbli

Classification

Therapeutic: Antihypertensive, Angiotensin II Receptor Blocker (ARB)

Pharmacological: Competitive AT1 receptor antagonist

FDA Approved Indications

Mechanism of Action

Losartan blocks the binding of angiotensin II to the AT1 receptor, resulting in vasodilation, decreased aldosterone secretion, and reduction in blood pressure; it also reduces glomerular hypertension in diabetic nephropathy.

Dosage and Administration

Adult: Typically 50 mg once daily, titrated up to 100 mg once daily based on response and tolerability.

Pediatric: Not recommended for children under 6 years. Dosing for older children depends on weight and clinical condition.

Geriatric: Start at lower dose due to increased sensitivity and risk of hypotension.

Renal Impairment: Adjust dose in patients with renal impairment; may be used cautiously.

Hepatic Impairment: Use with caution; no specific dose adjustment required.

Pharmacokinetics

Absorption: Well absorbed from GI tract, with about 33% bioavailability.

Distribution: Widely distributed, crosses placenta.

Metabolism: Metabolized in the liver to an active metabolite, EXP3174.

Excretion: Excreted primarily via urine and feces.

Half Life: Approximately 2 hours for losartan; active metabolite has a half-life of about 6-9 hours.

Contraindications

Precautions

Adverse Reactions - Common

Adverse Reactions - Serious

Drug-Drug Interactions

Drug-Food Interactions

Drug-Herb Interactions

Nursing Implications

Assessment: Monitor blood pressure, serum potassium, renal function (BUN, serum creatinine) regularly.

Diagnoses:

  • Risk for electrolyte imbalance
  • Risk for hypotension

Implementation: Administer as prescribed, monitor patient response, educate about symptom reporting.

Evaluation: Assess blood pressure for effectiveness; monitor for signs of hyperkalemia or renal impairment.

Patient/Family Teaching

Special Considerations

Black Box Warnings:

Genetic Factors: Genetic polymorphisms may influence response to therapy.

Lab Test Interference: May increase serum potassium and serum creatinine.

Overdose Management

Signs/Symptoms: Severe hypotension, tachycardia or bradycardia, electrolyte disturbances.

Treatment: Supportive care, monitor vital signs, correct electrolyte imbalances, administer vasopressors if needed.

Storage and Handling

Storage: Store at room temperature, away from moisture and light.

Stability: Stable for 2-3 years when stored properly.

This guide is for educational purposes only and is not intended for clinical use.